---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-048850"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T18:35:29.196472+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix appoints Pravin Dugel as CEO, Nadia Waheed as CMO; stock plan increased

## Summary
- Pravin U. Dugel appointed President and CEO, effective April 14, 2024; he remains Executive Chairman.
- Prior CEO Antony C. Mattessich resigned; severance includes 24 months base salary and 24-month equity acceleration.
- Nadia Waheed appointed Chief Medical Officer effective May 20, 2024, replacing Rabia Gurses Ozden.
- 2019 Inducement Stock Incentive Plan amended to increase shares from 3,804,000 to 4,804,000.

## SEC filing metadata
- accession: 0001104659-24-048850
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/tm2412141d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-048850
- JSON: https://secwatch.observer/filing/0001104659-24-048850.json
- Plain text: https://secwatch.observer/filing/0001104659-24-048850.txt

## Key facts
- Executive change
  Pravin U. Dugel, M.D. was appointed as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On April 14, 2024 (the “Transition Date”), the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Pravin U. Dugel, M.D., to serve as President and Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm
- Executive change
  Antony C. Mattessich resigned as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On the Transition Date, Dr. Dugel succeeded Antony C. Mattessich as the Company’s President and Chief Executive Officer, and Mr. Mattessich resigned from the board of directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm
- Executive change
  Rabia Gurses Ozden, M.D. departed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.
  - Action: ceased
  - Role: Chief Medical Officer
  source text: Effective upon the commencement of Dr. Waheed’s employment, Rabia Gurses Ozden, M.D., will cease to serve as the company’s Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm
- Executive change
  Nadia Waheed, M.D. was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.
  - Action: appointed
  - Role: Chief Medical Officer
  source text: On April 16, 2024, the Company announced that Nadia Waheed, M.D., had been appointed to serve as Chief Medical Officer of the Company, effective upon the anticipated commencement of her employment with the Company on May 20, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.